| Literature DB >> 29873261 |
Fang Chen1,2, Yingkun He1,3, Pengwen Wang1,2, Peng Wei1,4, Huili Feng1,2, Yingxue Rao1,5, Jing Shi1,6, Jinzhou Tian1,6.
Abstract
Reduced glucose utilization and deficient energy metabolism that occur in the early stages of Alzheimer's disease correlate with impaired cognition, and this information is evidence that Alzheimer's disease is a metabolic disease that is associated with brain insulin/insulin-like growth factor resistance. This research aimed to investigate the effects of Banxia Xiexin decoction (BXD) on cognitive deficits in APPswe/PS1dE9 double transgenic mice and verify the hypothesis that BXD treatment improves cognitive function via improving insulin signalling, glucose metabolism and synaptic plasticity in the hippocampus of APPswe/PS1dE9 double transgenic mice. We used 3-month-old APPswe/PS1dE9 double transgenic mice as the case groups and wild-type littermates of the double transgenic mice from the same colony as the control group. Forty-five APPswe/PS1dE9 double transgenic mice were randomly divided into the model group, donepezil group and BXD group. The mice in the control and model groups were administered 0.5% carboxymethyl cellulose orally. The Morris water maze and step-down test were conducted to evaluate the cognitive performance of APPswe/PS1dE9 double transgenic mice after BXD treatment. Ultrastructure of synapses was observed in the hippocampal CA1 area. Proteins involved in insulin signalling pathways and glucose transports in the hippocampus were assessed through immunohistochemical staining and western blot. After 3 months intervention, we found that BXD treatment improved cognitive performance and the synaptic quantity and ultrastructure, restored insulin signalling and increased the expression of glucose transporter 1 (GLUT1) and GLUT3 levels. These findings suggest that the beneficial effect of BXD on cognition may be due to the improvement of insulin signalling, glucose metabolism and synaptic plasticity.Entities:
Keywords: Alzheimer’s disease; cognition; glucose metabolism; insulin signalling; synapse
Mesh:
Substances:
Year: 2018 PMID: 29873261 PMCID: PMC5992807 DOI: 10.1177/2058738418780066
Source DB: PubMed Journal: Int J Immunopathol Pharmacol ISSN: 0394-6320 Impact factor: 3.219
Figure 1.Effect of BXD on APPswe/PS1dE9 double transgenic mice in the Morris water maze test and step-down test. (a) Escape latency of MWM test. Graphs show mean time ± SD taken to reach the platform (escape latency) for days 1 through 5. The escape latency of the BXD group was shorter than that of the model group on day 3 and day 4. (b) Swimming distance. The swimming distance of the mice in the BXD group was significantly decreased on days 2–3 and day 5. (c) Objective quadrant retention time. The residence time in the target quadrant of the mice in the BXD group was longer than that of the model group. (d) Latency of step-down test. The latency of step-down was significantly longer in the BXD group compared to that of the model group. Data are represented as means ± SD. #P < 0.05 versus the WT group, ##P < 0.01 versus the WT group, *P < 0.05 versus the TG group, **P < 0.01 versus the TG group.
Figure 2.(a) Ultrastructure of synapses in the APPswe/PS1dE9 double transgenic mice: (i) the synapses in the control group, appeared normal with a vivid presynaptic and postsynaptic membrane and synaptic cleft, (ii) in the model group, synaptic vesicles with different shapes and sizes could be observed in the presynaptic membrane, (iii) the synapse in the DNP group was almost normalized and (iv) in the BXD group, synapses were improved. (b) Immunohistochemical staining of PI3K. Compared with the model group, PI3K-stained cells in the DNP and BXD groups were significantly more than those in the model group. Data are represented as means ± SD. #P < 0.05 versus the WT group, ##P < 0.01 versus the WT group, *P < 0.05 versus the TG group, **P < 0.01 versus the TG group. (c) Immunohistochemical staining of Akt. Compared with the model group, Akt-stained cells in the DNP and BXD groups were significantly more than those in the model group. Data are represented as means ± SD. #P < 0.05 versus the WT group, ##P < 0.01 versus the WT group, *P < 0.05 versus the TG group, **P < 0.01 versus the TG group.
Synapses counting in different groups by transmission electron microscopy (scale bars = 1.5 μm).
| Group | Field of
vision | Mean | ||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| Cont | 30 | 25 | 24 | 26 | 26 | 26.2 |
| Mod | 10 | 11 | 9 | 12 | 10 | 10.4 |
| DNP | 24 | 26 | 22 | 23 | 26 | 24.2 |
| BXD | 23 | 22 | 22 | 19 | 18 | 20.8 |
DNP: donepezil; BXD: Banxia Xiexin decoction.
Figure 3.(a)–(c) The expression of PI3K, Akt and p-Akt in the hippocampus of APPswe/PS1dE9 double transgenic mice. Western blot analysis showed that a significant down-regulation of PI3K, Akt and p-Akt in the hippocampus of the mice in the model group compared with the control group. After BXD treatment, the expression of PI3K, Akt and p-Akt was elevated compared with the model group. Data are represented as means ± SD. #P < 0.05 versus the WT group, ##P < 0.01 versus the WT group, *P < 0.05 versus the TG group, **P < 0.01 versus the TG group. (d, e) The expression of GLUT 1 and GLUT 3 in the hippocampus of APPswe/PS1dE9 double transgenic mice. Western blot showed that the expression of GLUT 1 and GLUT 3 in the BXD group was increased compared with that of the model group. Data are represented as means ± SD. #P < 0.05 versus the WT group, ##P < 0.01 versus the WT group, *P < 0.05 versus the TG group, **P < 0.01 versus the TG group.